Profound Med Corp Stock Price, News & Analysis

Profound Medical (NASDAQ:PROF) will present an update at the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025 at 1:20 p.m. ET in New York City. Management's presentation will be broadcast live and later archived on the company's investor website under News & Events.

The company describes itself as a commercial-stage medical device maker of customizable, AI-powered, incision-free therapies for tissue ablation.

Profound Medical (NASDAQ:PROF) announced preliminary unaudited Q3 2025 revenue of $5.2M–$5.3M, representing 84%–87% YoY growth versus $2.8M in Q3 2024. Gross margin is expected to be ~72%, up from 64% a year ago. The company reported its TULSA-PRO installed base at 67, up from 60, and said it still expects to reach at least 75 systems by year-end.

These figures are preliminary and unaudited; full Q3 2025 results will be released after market close on November 13, 2025, followed by a conference call at 4:30 p.m. ET.

Profound Medical Corp. (NASDAQ:PROF) announced a groundbreaking partnership between Texas Prostate and Dallas Medical Center to launch a first-of-its-kind TULSA program. The collaboration expands Medicare patient access to the TULSA Procedure™, an advanced, AI-powered prostate treatment technology.

The program enables Texas Prostate to perform TULSA procedures at Dallas Medical Center's MRI suite, treating both prostate cancer and benign prostatic hyperplasia (BPH). This advancement follows Medicare's coverage approval in January 2025 for TULSA procedures across various healthcare settings.

The TULSA-PRO® system represents a significant innovation in prostate care, utilizing robotically-guided ultrasound within an MRI environment to precisely ablate targeted prostate tissue. The procedure offers key advantages including same-day discharge, no procedural blood loss, and reduced risk of complications like incontinence or erectile dysfunction.

Profound Medical (NASDAQ:PROF), a commercial-stage medical device company specializing in incision-free tissue ablation therapies, will participate in the Lake Street Capital Markets "BIG9" Conference on September 11, 2025 in New York City. The company's management will engage in one-on-one meetings with investors during the conference. No webcast will be available for this event due to its format.

Profound Medical (NASDAQ:PROF) reported Q2 2025 financial results, with revenue of $2.2 million, unchanged year-over-year, comprising $1.6 million from recurring revenue and $650,000 from capital equipment sales. The company's gross margin improved to 73% from 64% in the prior year.

TULSA-PRO® system showed strong operational metrics with 10% sequential growth in procedure volumes and a pipeline of 80 new systems in various sales stages. The company launched TULSA-AI® Volume Reduction Module for BPH treatment and appointed Leonard Wheeler as Global Ambassador. Despite some delayed capital sales, Profound maintains its guidance of 70-75% year-over-year revenue growth for 2025.

Profound Medical (NASDAQ:PROF), a commercial-stage medical device company specializing in incision-free tissue ablation therapies, has scheduled its second quarter 2025 financial results announcement for August 14, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET on the same day, where management will review financial results and discuss business developments. Investors can access the call through registration and listen to the live broadcast on the company's website.

Profound Medical (NASDAQ:PROF) has announced the first commercial BPH treatment using TULSA-PRO® with its new TULSA-AI® Volume Reduction Module. The procedure was performed by Dr. Naveen Kella at The Urology Place. The TULSA-AI® enhancement streamlines treatment planning and reduces procedure time to 60-90 minutes for BPH patients. A recent study from the University of Turku demonstrated TULSA's effectiveness in treating BPH, showing significant improvements in urinary function while preserving sexual function. The treatment offers advantages over traditional methods like TURP, requiring no hospital stay and causing no bleeding. TULSA uses real-time MR guidance and AI-enhanced planning to precisely treat prostate tissue. The company expects this advancement to expand their annual market opportunity from 200,000 to 600,000 prostate disease patients.

Profound Medical Corp (NASDAQ:PROF) has appointed former NFL safety Leonard Wheeler as Global Ambassador for its TULSA-PRO system. Wheeler, who successfully underwent the TULSA procedure for prostate cancer in early 2025, will lead education and awareness initiatives for the company's innovative treatment. The TULSA-PRO system offers an AI-powered, incision-free therapy for prostate conditions, including cancer and BPH, using real-time MR guidance and sound absorption technology. Wheeler, a nine-year NFL veteran turned executive coach and entrepreneur, brings extensive experience in leadership and public speaking through his company Trilucent Global. His personal experience with TULSA-PRO and successful treatment at The Busch Center positions him uniquely to advocate for this alternative to traditional prostate treatments. The partnership aims to expand awareness and adoption of TULSA-PRO among physicians, patients, and private payers through various media channels.

Profound Medical Corp (NASDAQ: PROF) held its Annual General and Special Meeting with strong shareholder participation, as 68.5% of outstanding shares (20,587,011 shares) were represented. All six director nominees were successfully elected to the Board with approval rates ranging from 92.4% to 97%. The highest approval was received by Cynthia Lavoie (97%), while Arthur Rosenthal received the lowest support (92.4%). Shareholders also approved the appointment of PricewaterhouseCoopers LLP as the company's auditor and passed a resolution approving unallocated options under the company's share option plan.